These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37097811)

  • 1. Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy.
    Fan R; Chen C; Mu M; Chuan D; Liu H; Hou H; Huang J; Tong A; Guo G; Xu J
    ACS Nano; 2023 May; 17(10):9126-9139. PubMed ID: 37097811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
    Hu J; Jiang C; Zheng M; Guo Y; Tang X; Ren J; Lu D; Yu L; Gan W; Liu S; Tong A; Yang H
    Am J Transl Res; 2019; 11(8):5183-5196. PubMed ID: 31497233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies in cancer immunotherapy.
    Rader C
    Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
    Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
    Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 7. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.
    Liu B; Ji Q; Cheng Y; Liu M; Zhang B; Mei Q; Liu D; Zhou S
    J Nanobiotechnology; 2022 Mar; 20(1):161. PubMed ID: 35351131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting T cells with bispecific antibodies for cancer therapy.
    Lum LG; Thakur A
    BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
    Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM.
    Feng S; Liang X; Li J; Wang Z; Zhang H; Dai Z; Luo P; Liu Z; Zhang J; Xiao X; Cheng Q
    Front Immunol; 2022; 13():992855. PubMed ID: 36248827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
    Liu T; Zhu C; Chen X; Guan G; Zou C; Shen S; Wu J; Wang Y; Lin Z; Chen L; Cheng P; Cheng W; Wu A
    Neuro Oncol; 2022 Jul; 24(7):1113-1125. PubMed ID: 35148413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron oxide nanoparticles loaded with paclitaxel inhibits glioblastoma by enhancing autophagy-dependent ferroptosis pathway.
    Chen H; Wen J
    Eur J Pharmacol; 2022 Apr; 921():174860. PubMed ID: 35278406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.